1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86.
Article
2. Alonso DF, Skilton G, Farias EF, Bal de Kier Joffe E, Gomez DE. Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Res Treat. 1999; 57:271–5.
Article
3. Ripoll GV, Garona J, Pifano M, Farina HG, Gomez DE, Alonso DF. Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. Breast Cancer Res Treat. 2013; 142:9–18.
Article
4. Kaufmann JE, Oksche A, Wollheim CB, Gunther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000; 106:107–16.
Article
5. Pifano M, Garona J, Capobianco CS, Gonzalez N, Alonso DF, Ripoll GV. Peptide agonists of vasopressin V2 receptor reduce expression of neuroendocrine markers and tumor growth in human lung and prostate tumor cells. Front Oncol. 2017; 7:11.
Article
6. Ripoll GV, Garona J, Hermo GA, Gomez DE, Alonso DF. Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer. Anticancer Res. 2010; 30:5049–54.
7. Mochizuki S, Soejima K, Shimoda M, Abe H, Sasaki A, Okano HJ, et al. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst. 2012; 104:906–22.
Article
8. Terraube V, Marx I, Denis CV. Role of von Willebrand factor in tumor metastasis. Thromb Res. 2007; 120 Suppl 2:S64–70.
Article
9. Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and inflammation. J Thromb Haemost. 2017; 15:1285–94.
Article
10. Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011; 117:1071–80.
Article
11. Weinberg RS, Grecco MO, Ferro GS, Seigelshifer DJ, Perroni NV, Terrier FJ, et al. A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. Springerplus. 2015; 4:428.
Article
12. Czaplewski C, Kazmierkiewicz R, Ciarkowski J. Molecular modeling of the human vasopressin V2 receptor/agonist complex. J Comput Aided Mol Des. 1998; 12:275–87.
13. Kowalczyk W, Prahl A, Derdowska I, Sobolewski D, Olejnik J, Zabrocki J, et al. Analogues of neurohypophyseal hormones, oxytocin and arginine vasopressin, conformationally restricted in the N-terminal part of the molecule. J Med Chem. 2006; 49:2016–21.
Article
14. Pastrian MB, Guzman F, Garona J, Pifano M, Ripoll GV, Cascone O, et al. Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells. Mol Med Rep. 2014; 9:2568–72.
Article
15. Garona J, Pifano M, Orlando UD, Pastrian MB, Iannucci NB, Ortega HH, et al. The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models. Int J Oncol. 2015; 46:2335–45.
16. Iannucci NB, Ripoll GV, Garona J, Cascone O, Ciccia GN, Gomez DE, et al. Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells. Future Med Chem. 2011; 3:1987–93.
Article
17. Monstein HJ, Truedsson M, Ryberg A, Ohlsson B. Vasopressin receptor mRNA expression in the human gastrointestinal tract. Eur Surg Res. 2008; 40:34–40.
Article
18. Marques I, Araujo A, de Mello RA. Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. World J Gastroenterol. 2013; 19:7955–71.
Article
19. Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics. 2014; 15:190.
Article
20. Khan S, Cameron S, Blaschke M, Moriconi F, Naz N, Amanzada A, et al. Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines. World J Gastroenterol. 2014; 20:2979–94.
21. Riihimaki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016; 6:29765.
Article
22. Kim KY, Kim NK, Cha IH, Ahn JB, Choi JS, Choi GH, et al. Novel methods for clinical risk stratification in patients with colorectal liver metastases. Cancer Res Treat. 2015; 47:242–50.
Article
23. Rmali KA, Puntis MC, Jiang WG. Tumour-associated angiogenesis in human colorectal cancer. Colorectal Dis. 2007; 9:3–14.
Article
24. Ripoll G, Iannucci N, Giron S, Cascone O, Gomez D, Alonso D. Angiostatic activity of 1-deamino-8-D-arginine vasopressin and novel peptide analogues in breast cancer cells. Cancer Res. 2008; 68(9 Suppl):295.
25. Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol. 2015; 12:213–26.
Article
26. Hirai T, Matsumoto H, Kubota H, Yamaguchi Y. Regulating surgical oncotaxis to improve the outcomes in cancer patients. Surg Today. 2014; 44:804–11.
Article
27. Pifano M, Garona J, Sobol NT, Alberto M, Alonso DF, Ripoll GV. Search of vasopressin analogs with antiproliferative activity on small-cell lung cancer: drug design based on two different approaches. Future Med Chem. 2018; 10:879–94.
Article
28. McEwan DG, Brunton VG, Baillie GS, Leslie NR, Houslay MD, Frame MC. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res. 2007; 67:5248–57.
Article
29. Loffler I, Grun M, Bohmer FD, Rubio I. Role of cAMP in the promotion of colorectal cancer cell growth by prostaglandin E2. BMC Cancer. 2008; 8:380.
Article
30. Hopfner M, Maaser K, Barthel B, von Lampe B, Hanski C, Riecken EO, et al. Growth inhibition and apoptosis induced by P2Y2 receptors in human colorectal carcinoma cells: involvement of intracellular calcium and cyclic adenosine monophosphate. Int J Colorectal Dis. 2001; 16:154–66.
Article